The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX

BACKGROUND: The intravenous, rapidly acting P2Y12 inhibitor cangrelor reduces the rate of ischemic events during PCI with no significant increase in severe bleeding. However, the efficacy and safety of cangrelor compared with clopidogrel in patients treated with single vessel (SV)‐percutaneous coron...

Descripción completa

Detalles Bibliográficos
Autores principales: Yong, Celina M., Sundaram, Vandana, Abnousi, Freddy, Olivier, Christoph B., Yang, Jaden, Stone, Gregg W., Steg, Philippe G., Michael Gibson, C., Hamm, Christian W., Price, Matthew J., Deliargyris, Efthymios N., Prats, Jayne, White, Harvey D., Harrington, Robert A., Bhatt, Deepak L., Mahaffey, Kenneth W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2019
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727881/
https://www.ncbi.nlm.nih.gov/pubmed/31254472
http://dx.doi.org/10.1002/clc.23221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727881/
https://www.ncbi.nlm.nih.gov/pubmed/31254472
http://dx.doi.org/10.1002/clc.23221

Ejemplares similares